181 related articles for article (PubMed ID: 36118132)
21. Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies.
Pan M; Jiang C; Zhang Z; Achacoso N; Solorzano-Pinto AV; Tse P; Chung E; Suga JM; Thomas S; Habel LA
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345003
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic Characteristics of BRG1-Deficient NSCLC.
Dagogo-Jack I; Schrock AB; Kem M; Jessop N; Lee J; Ali SM; Ross JS; Lennerz JK; Shaw AT; Mino-Kenudson M
J Thorac Oncol; 2020 May; 15(5):766-776. PubMed ID: 31988001
[TBL] [Abstract][Full Text] [Related]
23. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Spira AI; Tu H; Aggarwal S; Hsu H; Carrigan G; Wang X; Ngarmchamnanrith G; Chia V; Gray JE
Lung Cancer; 2021 Sep; 159():1-9. PubMed ID: 34293517
[TBL] [Abstract][Full Text] [Related]
24. Primary Resistance to Immune Checkpoint Blockade in an
Kwack WG; Shin SY; Lee SH
Onco Targets Ther; 2020; 13():8901-8905. PubMed ID: 32982282
[TBL] [Abstract][Full Text] [Related]
25. KRAS
Frost N; Kollmeier J; Vollbrecht C; Grah C; Matthes B; Pultermann D; von Laffert M; Lüders H; Olive E; Raspe M; Mairinger T; Ochsenreither S; Blum T; Hummel M; Suttorp N; Witzenrath M; Grohé C
Transl Lung Cancer Res; 2021 Feb; 10(2):737-752. PubMed ID: 33718018
[TBL] [Abstract][Full Text] [Related]
26. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
[TBL] [Abstract][Full Text] [Related]
27. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J
J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727
[TBL] [Abstract][Full Text] [Related]
28. Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Tomasini P; Mascaux C; Jao K; Labbe C; Kamel-Reid S; Stockley T; Hwang DM; Leighl NB; Liu G; Bradbury PA; Pintilie M; Tsao MS; Shepherd FA
Clin Lung Cancer; 2019 May; 20(3):e338-e345. PubMed ID: 30770327
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics and prognostic value of the
Yuan Y; Liu Y; Wu Y; Zhang J; Shen C; Zhang F; Wu C; Hu W
Int J Biol Markers; 2021 Jun; 36(2):33-39. PubMed ID: 34044655
[TBL] [Abstract][Full Text] [Related]
30. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
[TBL] [Abstract][Full Text] [Related]
31. Clinical Characteristics and Outcomes in Advanced
Lee J; Tan AC; Zhou S; Yoon S; Liu S; Masuda K; Hayashi H; Batra U; Kim DW; Goto Y; Tan SH; Wu YL; Lee DH; Tan DSW; Ahn MJ
JTO Clin Res Rep; 2022 Jan; 3(1):100261. PubMed ID: 35024639
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of T cell receptor repertoire in patients with
Wang Y; Peng L; Zhao M; Xiong Y; Xue J; Li B; Huang Z; Liu X; Yang X; Song Y; Bing Z; Guo C; Tian Z; Gao C; Cao L; Cao Z; Li J; Jiang X; Si X; Zhang L; Li X; Zheng Z; Song M; Chen R; Lim WT; Pavan A; Romero A; Liang N; Yang H; Li S
Transl Lung Cancer Res; 2022 Sep; 11(9):1936-1950. PubMed ID: 36248331
[TBL] [Abstract][Full Text] [Related]
33. LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
Facchinetti F; Bluthgen MV; Tergemina-Clain G; Faivre L; Pignon JP; Planchard D; Remon J; Soria JC; Lacroix L; Besse B
Lung Cancer; 2017 Oct; 112():62-68. PubMed ID: 29191602
[TBL] [Abstract][Full Text] [Related]
34. Outcome analysis of Phase I trial patients with metastatic
Wang Y; Wang Z; Piha-Paul S; Janku F; Subbiah V; Shi N; Hess K; Broaddus R; Shan B; Naing A; Hong D; Tsimberidou AM; Karp D; Lu C; Papadimitrakopoulou V; Heymach J; Meric-Bernstam F; Fu S
Oncotarget; 2018 Sep; 9(70):33258-33270. PubMed ID: 30279957
[No Abstract] [Full Text] [Related]
35. Characterization of distinct types of
Jia Y; Jiang T; Li X; Zhao C; Zhang L; Zhao S; Liu X; Qiao M; Luo J; Shi J; Yang H; Wang Y; Xi L; Zhang S; Gao G; Su C; Ren S; Zhou C
Oncol Lett; 2017 Dec; 14(6):6525-6532. PubMed ID: 29163686
[TBL] [Abstract][Full Text] [Related]
36. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
[TBL] [Abstract][Full Text] [Related]
37. The role of distinct co-mutation patterns with
Wang S; Jiang M; Yang Z; Huang X; Li N
Genes Dis; 2022 Jan; 9(1):245-251. PubMed ID: 35005121
[No Abstract] [Full Text] [Related]
38. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
[TBL] [Abstract][Full Text] [Related]
39. Molecular Characteristics and the Effect of
Gu G; Yu B; Wan H; Lu S; Zhu X; Zhao Y; Fuxi Y; Liu C
Onco Targets Ther; 2022; 15():1021-1032. PubMed ID: 36172169
[TBL] [Abstract][Full Text] [Related]
40. The Prevalence and Concurrent Pathogenic Mutations of
Liu Y; Li H; Zhu J; Zhang Y; Liu X; Li R; Zhang Q; Cheng Y
Cancer Manag Res; 2021; 13():2447-2454. PubMed ID: 33758543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
